- Home
- Europe Cardiac Safety Services Market
Europe Cardiac Safety Services Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-477 | No of pages: 173 | Format:
Europe cardiac safety services market is projected to register a substantial CAGR of 14.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029
Market Segmentation:
Europe Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Europe cardiac safety services market are:
Technological advances in research and development, and drug discovery
Increase in prevalence of cardiovascular diseases
Market Players:
The key market players for Europe cardiac safety services market are listed below:
Koninklijke Philips N.V.
Laboratory Corporation of America Holdings
IQVIA
Medpace
Ncardia
Certara
Eurofins Scientific
SGS SA
Banook
Celerion
Biotrial
Richmond Pharmacology
PhysioStim
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 26 1.1 OBJECTIVES OF THE STUDY 26 1.2 MARKET DEFINITION 26 1.3 OVERVIEW OF EUROPE CARDIAC SAFETY SERVICES MARKET 26 1.4 LIMITATIONS 27 1.5 MARKETS COVERED 28 2 MARKET SEGMENTATION 30 2.1 MARKETS COVERED 30 2.2 GEOGRAPHICAL SCOPE 31 2.3 YEARS CONSIDERED FOR THE STUDY 32 2.4 CURRENCY AND PRICING 32 2.5 DBMR TRIPOD DATA VALIDATION MODEL 33 2.6 MULTIVARIATE MODELLING 36 2.7 SERVICES LIFELINE CURVE 36 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37 2.9 DBMR MARKET POSITION GRID 38 2.10 MARKET END USER GRID 40 2.11 VENDOR SHARE ANALYSIS 41 2.12 SECONDARY SOURCES 42 2.13 ASSUMPTIONS 42 3 EXECUTIVE SUMMARY 43 4 PREMIUM INSIGHTS 46 4.1 PORTERS FIVE FORCES 47 4.2 PESTEL ANALYSIS 48 5 EPIDEMIOLOGY 49 5.1 INCIDENCE OF ALL BY GENDER 49 5.2 TREATMENT RATE 50 5.3 MORTALITY RATE 50 5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 51 6 INDUSTRY INSIGHT 52 6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 52 6.2 PATENT ANALYSIS 53 6.3 PATENT FLOW DIAGRAM 54 6.4 KEY PATIENT ENROLLMENT STRATEGIES 54 6.5 PRICING STRATEGY 57 7 EUROPE CARDIAC SAFETY SERVICES MARKET: REGULATIONS 58 8 MARKET OVERVIEW 61 8.1 DRIVERS 63 8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS 63 8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING 63 8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 64 8.1.4 INCREASE IN R&D ACTIVITIES 64 8.2 RESTRAINTS 65 8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION 65 8.2.2 STRICT REGULATORY 65 8.3 OPPORTUNITIES: 66 8.3.1 INCREASE IN NEW DRUG DEVELOPMENT 66 8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES 67 8.4 CHALLENGES 67 8.4.1 TIME-CONSUMING PROCEDURE 67 8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION 68 9 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES 69 9.1 OVERVIEW 70 9.2 ECG/HOLTER MEASUREMENTS 74 9.3 BLOOD PRESSURE MEASUREMENTS 74 9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES 75 9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS 76 9.4.1.1 1 CONCENTRATIONS 76 9.4.1.2 4 CONCENTRATIONS 76 9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) 77 9.4.2.1 3 CONCENTRATIONS 77 9.4.2.2 5 CONCENTRATIONS 77 9.4.3 IN VITRO HERG ASSAY 77 9.4.4 OTHERS 77 9.5 CARDIOVASCULAR IMAGING 77 9.6 REAL TIME TELEMETRY MONITORING 78 9.7 CENTRAL OVER-READ OF ECGS 79 9.8 NON-INVASIVE CARDIAC IMAGING 79 9.9 PHYSIOLOGIC STRESS TESTING 80 9.10 THOROUGH QT STUDIES 81 9.11 TQT AND EXPOSURE RESPONSE MODELLING 81 9.12 PLATELET AGGREGATION 82 9.13 OTHERS 83 10 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE 84 10.1 OVERVIEW 85 10.2 PHASE I 88 10.3 PHASE II 88 10.4 PHASE III 89 11 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE 90 11.1 OVERVIEW 91 11.2 INTEGRATED SERVICES 94 11.3 STANDALONE SERVICES 95 12 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER 96 12.1 OVERVIEW 97 12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES 100 12.3 CONTRACT RESEARCH ORGANIZATIONS 100 12.4 ACADEMIC AND RESEARCH INSTITUTE 101 13 EUROPE CARDIAC SAFETY SERVICES MARKET, BY REGION 102 13.1 EUROPE 103 13.1.1 GERMANY 111 13.1.2 FRANCE 114 13.1.3 U.K. 117 13.1.4 ITALY 120 13.1.5 SPAIN 123 13.1.6 TURKEY 126 13.1.7 RUSSIA 129 13.1.8 NETHERLANDS 132 13.1.9 SWITZERLAND 135 13.1.10 BELGIUM 138 13.1.11 REST OF EUROPE 141 14 EUROPE CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE 142 14.1 COMPANY SHARE ANALYSIS: EUROPE 142 15 COMPANY PROFILE 143 15.1 EUROFINS SCIENTIFIC 143 15.1.1 COMPANY SNAPSHOT 143 15.1.2 REVENUE ANALYSIS 144 15.1.3 COMPANY SHARE ANALYSIS 144 15.1.4 PRODUCT PORTFOLIO 144 15.1.5 RECENT DEVELOPMENTS 145 15.1.5.1 AGREEMENTS 145 15.1.5.2 ACQUISITION 145 15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC) 146 15.2.1 COMPANY SNAPSHOT 146 15.2.2 REVENUE ANALYSIS 146 15.2.3 COMPANY SHARE ANALYSIS 147 15.2.4 PRODUCT PORTFOLIO 147 15.2.5 RECENT DEVELOPMENT 147 15.2.5.1 INVESTMENT 147 15.3 KONINKLIJKE PHILIPS N.V. 148 15.3.1 COMPANY SNAPSHOT 148 15.3.2 REVENUE ANALYSIS 148 15.3.3 COMPANY SHARE ANALYSIS 149 15.3.4 PRODUCT PORTFOLIO 149 15.3.5 RECENT DEVELOPMENT 149 15.3.5.1 ACQUISITION 149 15.4 IQVIA 150 15.4.1 COMPANY SNAPSHOT 150 15.4.2 REVENUE ANALYSIS 150 15.4.3 COMPANY SHARE ANALYSIS 151 15.4.4 PRODUCT PORTFOLIO 151 15.4.5 RECENT DEVELOPMENTS 151 15.4.5.1 ACQUISITION 151 15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 152 15.5.1 COMPANY SNAPSHOT 152 15.5.2 REVENUE ANALYSIS 152 15.5.3 COMPANY SHARE ANALYSIS 153 15.5.4 PRODUCT PORTFOLIO 153 15.5.5 RECENT DEVELOPMENTS 153 15.5.5.1 NEW LABORATORY 153 15.5.5.2 ACQUISITION 153 15.6 BANOOK 154 15.6.1 COMPANY SNAPSHOT 154 15.6.2 PRODUCT PORTFOLIO 154 15.6.3 RECENT DEVELOPMENT 154 15.6.3.1 AGREEMENT 154 15.7 BIOTRIAL 155 15.7.1 COMPANY SNAPSHOT 155 15.7.2 PRODUCT PORTFOLIO 155 15.7.3 RECENT DEVELOPMENT 155 15.7.3.1 NEW CENTER OPENING 155 15.8 CELERION 156 15.8.1 COMPANY SNAPSHOT 156 15.8.2 PRODUCT PORTFOLIO 156 15.8.3 RECENT DEVELOPMENT 156 15.8.3.1 NEW CENTER OPENING 156 15.9 CERTARA 157 15.9.1 COMPANY SNAPSHOT 157 15.9.2 REVENUE ANALYSIS 157 15.9.3 PRODUCT PORTFOLIO 158 15.9.4 RECENT DEVELOPMENTS 158 15.9.4.1 CONTRACT 158 15.9.4.2 ACQUISITION 158 15.10 CLARIO 159 15.10.1 COMPANY SNAPSHOT 159 15.10.2 PRODUCT PORTFOLIO 159 15.10.3 RECENT DEVELOPMENT 159 15.10.3.1 PRODUCT EXPANSION 159 15.11 MEDPACE 160 15.11.1 COMPANY SNAPSHOT 160 15.11.2 REVENUE ANALYSIS 160 15.11.3 PRODUCT PORTFOLIO 161 15.11.4 RECENT DEVELOPMENTS 161 15.11.4.1 ACQUISITION 161 15.12 NCARDIA 162 15.12.1 COMPANY SNAPSHOT 162 15.12.2 PRODUCT PORTFOLIO 162 15.12.3 RECENT DEVELOPMENT 162 15.12.3.1 PARTNERSHIP 162 15.13 NEXEL CO., LTD 163 15.13.1 COMPANY SNAPSHOT 163 15.13.2 PRODUCT PORTFOLIO 163 15.13.3 RECENT DEVELOPMENTS 163 15.13.3.1 JOINT VENTURE 163 15.13.3.2 PARTNERSHIP 164 15.14 PHYSIOSTIM 165 15.14.1 COMPANY SNAPSHOT 165 15.14.2 PRODUCT PORTFOLIO 165 15.14.3 RECENT DEVELOPMENT 165 15.14.3.1 PARTNERSHIP 165 15.15 RICHMOND PHARMACOLOGY 166 15.15.1 COMPANY SNAPSHOT 166 15.15.2 PRODUCT PORTFOLIO 166 15.15.3 RECENT DEVELOPMENT 166 15.15.3.1 EVENT 166 15.16 SGS SA 167 15.16.1 COMPANY SNAPSHOT 167 15.16.2 REVENUE ANALYSIS 167 15.16.3 PRODUCT PORTFOLIO 168 15.16.4 RECENT DEVELOPMENT 168 15.16.4.1 ACQUISITION 168 15.17 SHANGHAI MEDICILON INC. 169 15.17.1 COMPANY SNAPSHOT 169 15.17.2 PRODUCT PORTFOLIO 169 15.17.3 RECENT DEVELOPMENTS 169 15.17.3.1 PARTNERSHIP 169 15.17.3.2 PARTNERSHIP 170 16 QUESTIONNAIRE 171 17 RELATED REPORTS 173Segmentation
Short Description Europe Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029 Market Definition: Cardiac safety services generally help support and design clinical trials and other research needed to monitor heart safety. The demand for cardiac safety services market has been increased in both developed well as in developing countries and the reason behind this is the increasing number of clinical trials and product launch. The cardiac safety services market is growing due to introduction of innovative products, increasing in technological products and rising disposable income. The market will grow in forecasted period due to exploration of emerging markets, strategic initiatives by market players, increasing healthcare expenditure. Market Segmentation: The cardiac safety services market is categorized into four notable segment which is services, type, phase and end user. On the basis of services, the cardiac safety services market is segmented into ECG/Holter measurements, blood pressure measurements, in vitro cardiac safety assessment services, cardiovascular imaging, real-time telemetry monitoring, central over-read of ECGS, non-invasive cardiac imaging, physiologic stress testing, thorough QT studies, TQT and exposure response modeling, platelet aggregation and other services. On the basis of phases, the cardiac safety services market is segmented into phase 1, phase 2 and phase 3. In 2022, phase 1 is expected to dominate the global cardiac safety services market with the increasing new drug development and rising strategic initiatives by major market players. On the basis of type, the cardiac safety services market is segmented into integrated services and standalone services. In 2022, integrated services is expected to dominate the global cardiac safety services market with the increasing advanced technology and rising healthcare expenditure. On the basis of end user, the cardiac safety services market is segmented pharmaceuticals & biopharmaceuticals companies, contract research organizations and academic and research institute. In 2022, hospital is expected to dominate the global cardiac safety services market with the increasing number of patients and surgeries. Market Players The key market players for Europe cardiac safety services market are listed below: Koninklijke Philips N.V. Laboratory Corporation of America Holdings IQVIA Medpace Ncardia Certara Eurofins Scientific SGS SA Banook Celerion Biotrial Richmond Pharmacology PhysioStimMethodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.